NantKwest (formerly Conkwest)

General Information

We are a pioneering clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Natural killer, or NK, cells are the body’s first line of defense due to their innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support molecules required to activate adaptive immune cells such as T-cells. We believe that our proprietary NK cell line, coupled with our planned integrated discovery ecosystem, uniquely positions us to implement precision cancer medicine and potentially change the current paradigm of cancer care by leveraging the advances that have evolved during the past decade and addressing newly discovered challenges of cancer.

Employees: 15
Founded: 2002
Contact Information
Address 2533 South Coast Highway 101, Suite 210, Cardiff-by-the-Sea, CA 92007, US
Phone Number (858) 633-0300
Web Address
View Prospectus: NantKwest (formerly Conkwest)
Financial Information
Market Cap $1973.3mil
Revenues $0.5 mil (last 12 months)
Net Income $-37.9 mil (last 12 months)
IPO Profile
Symbol NK
Exchange NASDAQ
Shares (millions): 8.3
Price range $25.00 - $25.00
Est. $ Volume $207.2 mil
Manager / Joint Managers BofA Merrill Lynch/ Citigroup/ Jefferies/ Piper Jaffray
CO-Managers MLV & Co.
Expected To Trade: 7/28/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change